RB-pathway disruption in breast cancer: differential association with disease subtypes, disease-specific prognosis and therapeutic response. - Wikidata - wikimedia - TriplyDB

RB-pathway disruption in breast cancer: differential association with disease subtypes, disease-specific prognosis and therapeutic response.

RB-pathway disruption in breast cancer: differential association with disease subtypes, disease-specific prognosis and therapeutic response.

http://www.wikidata.org/entity/Q34659897

about

Low levels of Stat5a protein in breast cancer are associated with tumor progression and unfavorable clinical outcomes RB1: a prototype tumor suppressor and an enigma Retinoblastoma tumor suppressor pathway in breast cancer: prognosis, precision medicine, and therapeutic interventions Cyclin D as a therapeutic target in cancer Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer.Thymopoietin Beta and Gamma Isoforms as a Potential Diagnostic Molecular Marker for Breast Cancer: Preliminary Data.Identification of a genetic interaction between the tumor suppressor EAF2 and the retinoblastoma protein (Rb) signaling pathway in C. elegans and prostate cancer cells Cyclin D1 cooperates with p21 to regulate TGFβ-mediated breast cancer cell migration and tumor local invasion Targeting the cyclin D-cyclin-dependent kinase (CDK) 4/6-retinoblastoma pathway with selective CDK 4/6 inhibitors in hormone receptor-positive breast cancer: rationale, current status, and future directions Molecular profiling of a lethal tumor microenvironment, as defined by stromal caveolin-1 status in breast cancers.Progression of ductal carcinoma in situ to invasive breast cancer is associated with gene expression programs of EMT and myoepithelia.ChIP sequencing of cyclin D1 reveals a transcriptional role in chromosomal instability in mice.Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance.Claudin-low breast cancers: clinical, pathological, molecular and prognostic characterization Palbociclib (PD 0332991) : targeting the cell cycle machinery in breast cancer.Cooperativity of Rb, Brca1, and p53 in malignant breast cancer evolution.RB1 status in triple negative breast cancer cells dictates response to radiation treatment and selective therapeutic drugs.Ketones and lactate increase cancer cell "stemness," driving recurrence, metastasis and poor clinical outcome in breast cancer: achieving personalized medicine via Metabolo-Genomics Evidence for a stromal-epithelial "lactate shuttle" in human tumors: MCT4 is a marker of oxidative stress in cancer-associated fibroblasts.RB loss contributes to aggressive tumor phenotypes in MYC-driven triple negative breast cancer.Association of RB/p16-pathway perturbations with DCIS recurrence: dependence on tumor versus tissue microenvironment.RB-pathway disruption is associated with improved response to neoadjuvant chemotherapy in breast cancer.Hyperactivation of oxidative mitochondrial metabolism in epithelial cancer cells in situ: visualizing the therapeutic effects of metformin in tumor tissue.Molecular damage in cancer: an argument for mTOR-driven aging Retinoblastoma protein potentiates the innate immune response in hepatocytes: significance for hepatocellular carcinoma.Is cancer a metabolic rebellion against host aging? In the quest for immortality, tumor cells try to save themselves by boosting mitochondrial metabolism Loss of the N-terminal methyltransferase NRMT1 increases sensitivity to DNA damage and promotes mammary oncogenesis ErbB2 activation upregulates glutaminase 1 expression which promotes breast cancer cell proliferation Palbociclib for the Treatment of Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer.Tumour suppressor genes in chemotherapeutic drug response.FoxM1 regulates mammary luminal cell fate CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy.Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors.Modification of the DNA damage response by therapeutic CDK4/6 inhibition.Clinical utility of gene-expression profiling for tumor-site origin in patients with metastatic or poorly differentiated cancer: impact on diagnosis, treatment, and survival A Novel Retinoblastoma Protein (RB) E3 Ubiquitin Ligase (NRBE3) Promotes RB Degradation and Is Transcriptionally Regulated by E2F1 Transcription Factor.Identification of deregulation of apoptosis and cell cycle in neuroendocrine tumors of the lung via NanoString nCounter expression analysis.Overcoming Endocrine Resistance in Hormone-Receptor Positive Advanced Breast Cancer-The Emerging Role of CDK4/6 Inhibitors Activation of the glucocorticoid receptor is associated with poor prognosis in estrogen receptor-negative breast cancer.Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberine

P2860

Q21195193-C8814C61-9136-4C39-A2A9-2B428AFBAA3E Q26866393-7F55FFF2-5A04-4CBC-AFC8-D17193FDEA41 Q27022834-3014A7FF-294D-480F-AB02-2F27F82AD640 Q28242623-241C4A22-12E3-401D-8E63-2667E8BC136D Q30419997-A8016474-EEEC-4F48-9B95-9CD17E5791E8 Q30922764-D30D36C3-3985-4792-9DDC-9B62322493B5 Q33687691-A3F6ABD1-3CFF-45DE-AFA8-771159F41B81 Q33739855-A76FB367-BAA5-49C9-8262-F81D9733C8CE Q33816106-65E21F16-8346-4559-9A94-D4250B6B3D5C Q33882487-02949B0D-1375-4E16-AF72-37C21EB07008 Q34088976-610A4A82-0A0E-4AC4-A2D3-C1BC7951247C Q34252194-F06ECE6A-1AA0-41AD-9838-7A3FCE4F320C Q34307356-CB477A1B-74BB-4494-BD7D-0AD1570E838A Q34339847-D4E5D0BC-E80B-4BDA-B24B-BD5BDDCEA5F6 Q34394399-12C8A9BF-9F94-4540-BB27-CF07D598B6FB Q34485060-B9AE8D6C-B645-4D3C-A93D-91444715C7B3 Q35050328-A4C3D1CC-B865-4F24-9C41-0358DD5AC216 Q35051171-EA429496-4A23-4C8D-A022-C9F694188F28 Q35124597-B4613DF3-C315-46E6-995A-405946A1D492 Q35157633-47C97B60-5448-4026-834D-9BEFE224FEA7 Q35168174-62B51D28-A675-4811-B5F3-570423F1E138 Q35620241-7F945751-B59E-4F4A-B5A3-6BABC3C9276E Q35737581-C7B4AE63-5320-431D-9B82-29D69A5E3C95 Q35740772-95C43B7F-9778-45B9-8236-F0E22CE13D20 Q35786335-A2BB9970-BF27-47F0-B2B2-0D165A080E94 Q35801392-FED698CB-E6DA-460E-BF7B-950BAE02B3E8 Q35828551-ACD53E92-D5ED-4200-9B03-C9DD718C58FD Q35899955-395B5DE5-CFB3-43F0-8ECD-2E03CA13EDC6 Q35958082-5113AAD6-B7F5-4C7F-A505-AC748A9B2730 Q36083098-37800B9A-3E3A-465A-A26B-75331C748BC7 Q36106731-AA2951A4-040A-4B5E-AFF3-909155CB3651 Q36130084-8602972F-4E96-4EC0-8516-1DD1CCC27894 Q36130090-FBD68FEE-AE31-4F54-85A6-C5BE262E2041 Q36217351-F5FB073F-C154-401E-ADE2-80219CF6B7ED Q36234056-15D9A3A7-8138-4262-8B89-80AA537D8FC2 Q36301276-49E13C93-692F-4108-B217-E5F28C3D0188 Q36413013-3E8AC986-EFAD-4240-B223-40A59BC7EA52 Q36420373-3AD2EABC-A384-49E6-AF76-82177D96560F Q36445441-002DABD9-47EF-41F7-BCED-A4BA7F388A8F Q36556350-FC94FD43-25A0-4BFC-B547-4BA2CE4F4933

P2860

RB-pathway disruption in breast cancer: differential association with disease subtypes, disease-specific prognosis and therapeutic response.

http://www.wikidata.org/entity/Q34659897

description

2010 nî lūn-bûn

@nan

2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

RB-pathway disruption in breas ...... osis and therapeutic response.

@ast

RB-pathway disruption in breas ...... osis and therapeutic response.

@en

RB-pathway disruption in breas ...... osis and therapeutic response.

@nl

type

label

RB-pathway disruption in breas ...... osis and therapeutic response.

@ast

RB-pathway disruption in breas ...... osis and therapeutic response.

@en

RB-pathway disruption in breas ...... osis and therapeutic response.

@nl

prefLabel

RB-pathway disruption in breas ...... osis and therapeutic response.

@ast

RB-pathway disruption in breas ...... osis and therapeutic response.

@en

RB-pathway disruption in breas ...... osis and therapeutic response.

@nl

P1433

Q34659897-8EE7F334-1B68-4FEC-A2F0-31E6BFA92D74

P1476

Q34659897-0E95CACB-8AAB-4AF7-A4B0-E371342BF599

P2093

Q34659897-69ED6706-6DE6-46AC-9CB7-C295E2F8D9C3

Q34659897-AC01D5BA-EBFF-414F-8673-B05B876C7D44

Q34659897-CCCDB7C5-CD15-4862-A956-094D939D2D74

Q34659897-D2E3BA7D-4C65-4D09-99F1-1336085A9905

Q34659897-DF366EC6-9361-4F7D-B2A2-16EB50944F50

Q34659897-E7B91CC8-C525-4B82-B849-760D2AD46F50

P2860

Q34659897-0125A057-3575-4924-BF77-563F34E7D0B1

Q34659897-01D4A967-E13E-4161-896A-C7C84F996126

Q34659897-02E754CF-E3E6-463C-A24D-1F85C39BD3A4

Q34659897-0544DBE0-651A-4453-A94F-C2676B1DFFA6

Q34659897-0DA5506F-DFA7-4673-9A81-A36E8B84EDD3

Q34659897-10A6D4BA-E0D3-4634-917C-DE048A2D0A99

Q34659897-1A09EC2F-79C4-4E30-8D7E-00146142B809

Q34659897-1A3D57C2-2A01-4147-A62F-B19480AE489E

Q34659897-21EAF6E5-AADA-46D3-98A0-7F4FF34A72D4

Q34659897-25FBB045-4C21-470F-BD39-25FE06A2EF1E

P304

Q34659897-3AF68ADF-83CB-48C7-967A-0C6519206A40

P31

Q34659897-30B39595-1772-460A-83C2-F91668866CC1

P356

Q34659897-76608FB5-4E46-4049-8D70-C508961BBDB6

P433

Q34659897-46060807-4448-40A2-9350-E739B275056F

P478

Q34659897-F46C2657-C39D-4FFE-87DC-8E48D4FE93EB

P50

Q34659897-6D94C4E5-D826-4159-B4D7-20240D0B53EC

P577

Q34659897-D43F13AF-7B0F-4E13-A42C-C4F3EEC715A8

P5875

Q34659897-AEAB8EBA-2D98-481F-BA5E-065FBA2C9589

P698

Q34659897-81753931-2F09-4A7A-805B-BB6174981530

P932

Q34659897-536E40D2-78C1-437F-B430-C8268C25D6B7

P356

P1433

P1476

RB-pathway disruption in breas ...... osis and therapeutic response.

@en

P2093

Adam Ertel

http://www.w3.org/2001/XMLSchema#string

Agnes K Witkiewicz

http://www.w3.org/2001/XMLSchema#string

Chengbao Liu

http://www.w3.org/2001/XMLSchema#string

Erik S Knudsen

http://www.w3.org/2001/XMLSchema#string

Hallgeir Rui

http://www.w3.org/2001/XMLSchema#string

Jeffry L Dean

http://www.w3.org/2001/XMLSchema#string

P2860

Gene ontology: tool for the unification of biology

Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer

Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer

E2F integrates cell cycle progression with DNA repair, replication, and G(2)/M checkpoints

DAVID: Database for Annotation, Visualization, and Integrated Discovery

Cyclin D1 in breast cancer pathogenesis.

Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure.

Gene Expression Omnibus: NCBI gene expression and hybridization array data repository

Exploration, normalization, and summaries of high density oligonucleotide array probe level data

Pocket proteins and cell cycle control

P304

4153-4163

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4161/CC.9.20.13454

http://www.w3.org/2001/XMLSchema#string

P433

20

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

Karen E Knudsen

P577

2010-10-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

47429870

http://www.w3.org/2001/XMLSchema#string

P698

20948315

http://www.w3.org/2001/XMLSchema#string

P932

3055199

http://www.w3.org/2001/XMLSchema#string